CLINIMIX

Manufacturer: Baxter Healthcare Corporation | Baxter SA
Effective date: 2021-04-13
Label type: HUMAN PRESCRIPTION DRUG LABEL
Version: 14
Source: daily-update
Hydrated at: 2026-06-06 05:10:28

Label at a glance#

ProductCLINIMIX

Active ingredientLEUCINE, PHENYLALANINE, LYSINE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, SERINE, TYROSINE, DEXTROSE

Label structure14 sections

Indications and uses

CLINIMIX is indicated as a source of calories and protein for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX may be used to treat negative nitrogen balance in patients.

Dosage and administration

• CLINIMIX is available in a three port container configuration and a two port container configuration. o Three Port Container : the ports consist of one medication port, one additive port and one outlet port. Additives can be introduced to the container through the medication port and lipids through the additive port on the three port container. o Two Port Container : the ports consist of one medication port and ...

Storage and handling

CLINIMIX (amino acids in dextrose) injection (sulfite-free) is available in 1000 mL and 2000 mL volumes (See Table 9 ). Table 9: CLINIMIX Formulations (per 07-19-00-3604 and BE-30-03-648) After mixing, the product represents 1000 mL Code and NDC Number 2000 mL Code and NDC Number CLINIMIX 4.25/5 sulfite‑free (4.25% Amino Acid in 5% Dextrose) Injection Code 2B7726 NDC 0338‑1133‑03 Code 2B7704 NDC 0338‑1...

Contacts and useful links#

PhoneLabel contact826 990 1320

PhoneLabel contact880 880 1035

PhoneLabel contact675 930 1255

PhoneLabel contact1505 850 1308

PhoneLabel contact1-866-888-2472

PhoneFDA MedWatch1-800-FDA-1088

PhonePoison Help1-800-222-1222

Websitewww.fda.gov

www.fda.gov/medwatch

Websitewww.poison.org

www.poison.org

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Preparation Prior to Administration

SPL UNCLASSIFIED SECTION

CLINIMIX is available in a three port container configuration and a two port container configuration.
- Three Port Container: the ports consist of one medication port, one additive port and one outlet port. Additives can be introduced to the container through the medication port and lipids through the additive port on the three port container.
- Two Port Container: the ports consist of one medication port and one outlet port. Additives, including lipids, can be introduced to the container through the medication port on the two port container.
Tear protective overwrap at slit and remove solution container. Small amounts of moisture may be found on the solution container from water permeating from inside the container. The amount of permeated water is insufficient to affect the solution significantly. If larger amounts of water are found, the container should be checked for tears or leaks.
Inspect the container prior to activation. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Evaluate the following:
- If the outlet or additive port protectors are damaged, detached, or not present, discard container as solution path sterility may be impaired.
- Check to ensure seal between chambers is intact, solutions are contained in separate chambers, and the content of the individual chambers is clear, colorless or slightly yellow. Discard if the seal is broken or if the solution is bright yellow or yellowish brown.
- Check for minute leaks by separately squeezing each chamber. If external leaks or leakage between the chambers are found, discard solution as sterility or stability may be impaired.
Lipids and/or additives can be introduced to the container after opening seal between chambers. Because additives may be incompatible, evaluate all additions to the plastic container for compatibility. Activate chambers of container prior to introduction of additives. Mix thoroughly when additives have been introduced. Supplemental medication may be added with a 19 to 22 gauge needle through the medication port.
Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates [see Warnings and Precautions (5.1)].
Inspect the container to ensure precipitates have not formed during the mixing or addition of additives. A slight yellow color does not alter the quality and efficacy of this product. If lipid has been added, ensure the emulsion has not separated. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the mixed emulsion. Discard the admixture if any of the above are observed.

2.2 Important Administration Instructions

SPL UNCLASSIFIED SECTION

Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
Use a dedicated line without any connections to avoid air embolism.
CLINIMIX is for intravenous infusion only into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsm/L or greater must be infused through a central catheter [see Warnings and Precautions (5.6)].
- For central vein infusion only: CLINIMIX 4.25/10, 5/15, 5/20, 8/10, 8/14
- For central or peripheral vein infusion: CLINIMIX 4.25/5, 6/5
The solution should be inspected for precipitates before admixing, after admixing, and again before administration.
Use a 0.22 micron filter for administration of CLINIMIX. If a lipid is also administered, use a 1.2 micron filter.
If lipid emulsion is added, do not use administration sets and lines that contain di-2-ethylhexyl phthalate (DEHP). Administration sets that contain polyvinyl chloride (PVC) components have DEHP as a plasticizer.

2.3 Instructions for Use

SPL UNCLASSIFIED SECTION

Open by tearing protective overwrap at slit and remove solution container. The two port container includes an oxygen-absorbing sachet. Discard the oxygen-absorbing sachet after removal from the overwrap.
To proceed with activation, the container should be at room temperature. Lay the room temperature container onto a flat surface. Grasp the container firmly on each side of the top of the container (Figure 1).
Starting from the top, using some pressure, slowly roll the container to open seal between chambers as shown in Figure 2. Do not pull or rip the seal apart. The seal must be completely opened towards the port side of the container. The upper section of the seal towards the hanger side can remain unbroken.
Mix the contents thoroughly by inverting the container upside down to ensure a homogenous admixture (Figure 3).
Once the container is mixed, check for leaks.
Make additions (if prescribed).
Because additives may be incompatible, evaluate all additions to the container for compatibility and stability of the resulting preparation. Consult with pharmacist, if available. Questions about compatibility may be directed to Baxter. If it is deemed advisable to introduce additives, use aseptic technique. For information on adding lipid emulsions see Dosage and Administration (2.4) .
1. Prepare medication port.
2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
3. Mix solution and medication thoroughly (Figure 3). For high density medication (high specific gravity), such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
Inspect final solution for discoloration and particulate matter. Check for leaks.
8.Spike and hang container.
1. Suspend container from eyelet support.
2. Twist off protector from outlet port at bottom of container (Figure 4).
3. Attach administration set. Refer to complete directions accompanying set.

For single dose only. Discard unused portion.

Figures 1-4 (Three Port Container):

Figures 1-4 (Two Port Container):

Instructions on Storage

Storage After Removal of Overwrap:

Once removed from the protective overwrap, mixed (peel seal activated) or unmixed (peel seal intact) CLINIMIX solutions may be stored under refrigeration for up to 9 days.

Storage Once any Additive is Added:

Use promptly after mixing. Any storage with additives should be under refrigeration and limited to a brief period of time, less than 24 hours. After removal from refrigeration, use promptly and complete the infusion within 24 hours. Any remaining mixture must be discarded.

Protect the activated parenteral nutrition solution from light.

2.4 Preparation and Addition of Lipid Emulsion

SPL UNCLASSIFIED SECTION

Three Port Container

Prior to adding lipid emulsion, mix amino acid and dextrose injection as shown in Figures 1-3.
Prepare lipid emulsion transfer set following instructions provided.
Attach transfer set to lipid emulsion container using aseptic technique.
Twist off protector on the additive port of the container.
Attach the transfer set to the exposed additive port.
Open clamp on transfer set.
After completing transfer, use appropriate plastic clamp or metal ferrule to seal off additive port tube.
Remove transfer set.
Mix contents of container thoroughly. Inspect final solution for discoloration and particulate matter. Check for leaks.

Two Port Container

Prior to adding lipid emulsion, mix amino acid and dextrose injection as shown in Figures 1-3.
Prepare lipid emulsion transfer set following instructions provided.
Attach transfer set to lipid emulsion container using aseptic technique.
Prepare medication port.
Using a 19 to 22 gauge needle, puncture resealable medication port.
Open clamp on transfer set and transfer lipid emulsion.
Remove needle.
Mix contents of container thoroughly. Inspect final solution for discoloration and particulate matter. Check for leaks.

Storage Once Lipids are Added:

Use promptly after mixing. Any storage with additives should be under refrigeration and limited to a brief period of time, no longer than 24 hours. After removal from refrigeration, use promptly and complete the infusion within 24 hours. Any mixture remaining must be discarded.

2.5 Dosing Considerations

SPL UNCLASSIFIED SECTION

The dosage of CLINIMIX should be individualized based on the patient’s clinical condition (ability to adequately metabolize amino acids and dextrose), body weight and nutritional/fluid requirements, as well as additional energy given orally/enterally to the patient. Prior to initiating CLINIMIX the following patient information should be reviewed: all concomitant medications, gastrointestinal function and laboratory data such as electrolytes (including magnesium, calcium, and phosphorus), glucose, urea/creatinine, liver panel, complete blood count and triglyceride level (if adding lipid emulsion). Refer to the complete prescribing information of lipid emulsion for dosing information.
CLINIMIX formulations have varying concentrations of protein and carbohydrate; thus infusion rates to achieve requirements will vary. Protein, caloric, fluid and electrolyte requirements all need to be taken into consideration when determining individual patient dosage needs.
The dosage selection is based only on the recommended protein requirements. The maximum dextrose infusion rates and calorie and fluid requirements must also be considered when determining the clinically appropriate infusion rate for patients.
CLINIMIX meets the total nutritional requirements for protein and dextrose in stable patients, and can be individualized to meet specific needs with the addition of nutrients.
Total daily fluid requirements can be met beyond the volume of amino acids solution by supplementing with non-carbohydrate or carbohydrate-containing electrolyte solutions. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria.
Prior to administration of CLINIMIX correct severe fluid, electrolyte and acid-base disorders.
Monitor levels of serum potassium during therapy. It may be necessary to add potassium to the CLINIMIX admixture.
Lipid emulsion administration should be considered with prolonged use (more than 5 days) of CLINIMIX in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat-free parenteral nutrition. See prescribing information of lipid emulsion.
The flow rate should be increased gradually. The flow rate must be adjusted taking into account the dose being administered, the daily volume intake, and the duration of the infusion.

2.6 Recommended Dosage in Adults

SPL UNCLASSIFIED SECTION

The recommended daily nutritional requirements for protein and dextrose compared to the amount of nutrition provided by CLINIMIX are shown in Table 1.

As indicated on an individual basis, maintenance vitamins, electrolytes, trace elements and other components (including lipids) should be administered as required to prevent deficiencies and complications from developing.

The maximum infusion rates in adult patients are show in Table 2.

In addition to meeting protein needs, the administration rate should be governed, especially during the first few day of therapy, by the patient’s tolerance to dextrose. Daily intake of amino acids and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of blood glucose levels.

Table 1: Nutritional Comparison –Adult Patients
	Recommended CLINIMIX Adult Dosage
	CLINIMIX 4.25/5	CLINIMIX 4.25/10	CLINIMIX 5/15	CLINIMIX 5/20	CLINIMIX 6/5	CLINIMIX 8/10	CLINIMIX 8/14
Fluid (mL/kg/day)	19 to 40	19 to 40	16 to 40	16 to 40	13 to 33	10 to 25	10 to 25
Protein^*(g/kg/day) (Nitrogen g/kg/day)	0.8 to 1.7 (0.13 to 0.27)	0.8 to 1.7 (0.13 to 0.27)	0.8 to 2 (0.13 to 0.32)	0.8 to 2 (0.13 to 0.32)	0.8 to 2 (0.13 to 0.32)	0.8 to 2 (0.13 to 0.32)	0.8 to 2 (0.13 to 0.32)
Dextrose (g/kg/day)	0.95 to 2	1.9 to 4	2.4 to 6	3.2 to 8	0.65 to 1.65	1 to 2.5	1.4 to 3.5

* Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.

Table 2: Maximum Infusion Rate in Adult Patients
		Maximum Infusion Rates in Adults Patients
		CLINIMIX 4.25/5	CLINIMIX 4.25/10	CLINIMIX 5/15	CLINIMIX 5/20	CLINIMIX 6/5	CLINIMIX 8/10	CLINIMIX 8/14
Maximum Infusion Rate (mL/kg/hour)		2.4	2.4	1.67	1.25	1.67	1.3	1.3
Corresponding infusion rate	Amino Acid (g/kg/hour)	0.1^*	0.1	0.08	0.06	0.1	0.1	0.1
Corresponding infusion rate	Dextrose (g/kg/hour)	0.12	0.24	0.25	0.25	0.08	0.13	0.18

* Rate limiting factor

2.7 Dosage Modifications in Patients with Kidney Disease

SPL UNCLASSIFIED SECTION

Prior to administration, correct severe fluid or electrolyte imbalances. Closely monitor serum electrolyte levels and adjust the volume of CLINIMIX administered as required [see Warnings and Precautions (5.10)].

Chronic kidney disease patients with less than nephrotic range proteinuria require 0.8 g of protein/kg/day. Chronic kidney disease patients with nephrotic range proteinuria require 0.8g of protein/kg/day plus 1g of protein for each gram of proteinuria. Patients needing dialysis should receive from 1.2 of protein/kg/day up to a maximum of 2.5 g of protein/kg/day depending on the nutritional status and the dialysis modality. Serum electrolyte levels should be closely monitored. The CLINIMIX dosage can be adjusted based on the severity of kidney disease, supplementing protein as indicated. If required, additional amino acids may be added to the CLINIMIX container or infused separately. Compatibility of additions should be evaluated by a pharmacist and questions may be directed to Baxter.

2.8 Recommended Dosage in Pediatric Patients

SPL UNCLASSIFIED SECTION

The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia [see Use in Specific Populations (8.4)]. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.

In pediatric patients, CLINIMIX is dosed on the basis of protein provided as amino acids. The recommended dosage, by age group is provided in Tables 3 - 6. Infusion rates are based on protein and do not take carbohydrates, fluid or electrolytes into consideration.

This product does not contain the amino acids cysteine and taurine, considered conditionally essential for neonates and infants. If possible, these amino acids should be added to this product if used in this pediatric population.

Table 3: Preterm and Term Infants Less than 1 Month of Age
	Recommended CLINIMIX Dosage in Preterm and Term Infants Less than 1 Month of Age
	CLINIMIX 4.25/5	CLINIMIX 4.25/10	CLINIMIX 5/15	CLINIMIX 5/20	CLINIMIX 6/5	CLINIMIX 8/10	CLINIMIX 8/14
Infusion Rate Range (mL/kg/hr)	2.9 to 3.9	2.9 to 3.9	2.5 to 3.3	2.5 to 3.3	2.1 to 2.8	1.6 to 2.1	1.6 to 2.1
Fluid (mL/kg/day)	70 to 94	70 to 94	60 to 79	60 to 79	50 to 67	38.4 to 50	38.4 to 50
Protein^* (g/kg/day) (Nitrogen g/kg/day)	3 to 4 (0.48 to 0.64)	3 to 4 (0.48 to 0.64)	3 to 4 (0.48 to 0.64)	3 to 4 (0.48 to 0.64)	3 to 4 (0.48 to 0.64)	3 to 4 (0.48 to 0.64)	3 to 4 (0.48 to 0.64)
Dextrose (g/kg/day)	3.5 to 4.7	7 to 9.4	9 to 11.9	12 to 15.8	2.5 to 3.4	3.8 to 5	5.4 to 7

* Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.

Table 4: Pediatric Patients 1 Month to Less than 1 Year of Age
	Recommended CLINIMIX Dosage in Pediatric Patients 1 Month to Less than 1 Year of Age
	CLINIMIX 4.25/5	CLINIMIX 4.25/10	CLINIMIX 5/15	CLINIMIX 5/20	CLINIMIX 6/5	CLINIMIX 8/10	CLINIMIX 8/14
Infusion Rate Range (mL/kg/hr)	2 to 2.9	2 to 2.9	1.7 to 2.5	1.7 to 2.5	1.4 to 2.1	1 to 1.6	1 to 1.6
Fluid (mL/kg/day)	48 to 70	48 to 70	41 to 60	41 to 60	33.6 to 50	24 to 38.4	24 to 38.4
Protein^* (g/kg/day) (Nitrogen g/kg/day)	2 to 3 (0.32 to 0.48)	2 to 3 (0.32 to 0.48)	2 to 3 (0.32 to 0.48)	2 to 3 (0.32 to 0.48)	2 to 3 (0.32 to 0.48)	2 to 3 (0.32 to 0.48)	2 to 3 (0.32 to 0.48)
Dextrose (g/kg/day)	2.4 to 3.5	4.8 to 7	6.1 to 9	8.2 to 12	1.7 to 2.5	2.4 to 3.8	3.4 to 5.4

* Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.

Table 5: Pediatric Patients 1 Year to Less than 11 Years of Age
	Recommended CLINIMIX Dosage in Pediatric Patients 1 Year to Less than 11 Years of Age
	CLINIMIX 4.25/5	CLINIMIX 4.25/10	CLINIMIX 5/15	CLINIMIX 5/20	CLINIMIX 6/5	CLINIMIX 8/10	CLINIMIX 8/14
Infusion Rate Range (mL/kg/hr)	1 to 2	1 to 2	0.8 to 1.7	0.8 to 1.7	0.7 to 1.4	0.5 to 1	0.5 to 1
Fluid (mL/kg/day)	24 to 48	24 to 48	19 to 41	19 to 41	16.8 to 33.6	12 to 24	12 to 24
Protein^*(g/kg/day) (Nitrogen g/kg/day)	1 to 2 (0.16 to 0.32)	1 to 2 (0.16 to 0.32)	1 to 2 (0.16 to 0.32)	1 to 2 (0.16 to 0.32)	1 to 2 (0.16 to 0.32)	1 to 2 (0.16 to 0.32)	1 to 2 (0.16 to 0.32)
Dextrose (g/kg/day)	1.2 to 2.4	2.4 to 4.8	2.9 to 6.1	3.8 to 8.2	0.8 to 1.7	1.2 to 2.4	1.7 to 3.4

* Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.

Table 6: Pediatric Patients 11 Years to 17 Years of Age
	Recommended CLINIMIX Dosage in Pediatric Patients 11 Years to 17 Years of Age
	CLINIMIX 4.25/5	CLINIMIX 4.25/10	CLINIMIX 5/15	CLINIMIX 5/20	CLINIMIX 6/5	CLINIMIX 8/10	CLINIMIX 8/14
Infusion Rate Range (mL/kg/hr)	0.8 to 1.5	0.8 to 1.5	0.7 to 1.3	0.7 to 1.3	0.6 to 1	0.4 to 0.8	0.4 to 0.8
Fluid (mL/kg/day)	19 to 36	19 to 36	17 to 31	17 to 31	14.4 to 24	9.6 to 19.2	9.6 to 19.2
Protein^*(g/kg/day) (Nitrogen g/kg/day)	0.8 to 1.5 (0.13 to 0.24)	0.8 to 1.5 (0.13 to 0.24)	0.8 to 1.5 (0.13 to 0.24)	0.8 to 1.5 (0.13 to 0.24)	0.8 to 1.5 (0.13 to 0.24)	0.8 to 1.5 (0.13 to 0.24)	0.8 to 1.5 (0.13 to 0.24)
Dextrose (g/kg/day)	1 to 1.8	1.9 to 3.6	2.5 to 4.7	3.4 to 6.2	0.7 to 1.2	1 to 1.9	1.4 to.2.7

* Protein is provided as amino acids. When infused intravenously amino acids are metabolized and utilized as the building blocks of protein.

2.9 Discontinuation of CLINIMIX

SPL UNCLASSIFIED SECTION

To reduce the risk of hypoglycemia after discontinuation, a gradual decrease in flow rate in the last hour of infusion should be considered.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

CLINIMIX injection is available in 1000 mL and 2000 mL dual chamber containers. The individual chambers contain essential and nonessential amino acids and dextrose. Table 7 describes the individual components of CLINIMIX.

Table 7: INGREDIENTS PER 100mL OF CLINIMIX
Strength of CLINIMIX		CLINIMIX 4.25/5 sulfite‑free (4.25% Amino Acid in 5% Dextrose) Injection	CLINIMIX4.25/10 sulfite‑free (4.25% Amino Acid in 10% Dextrose) Injection	CLINIMIX 5/15 sulfite‑free (5% Amino Acid in 15% Dextrose) Injection	CLINIMIX 5/20 sulfite‑free (5% Amino Acid in 20% Dextrose) Injection	CLINIMIX 6/5 sulfite‑free (6% Amino Acid in 5% Dextrose) Injection	CLINIMIX 8/10 sulfite‑free (8% Amino Acid in 10% Dextrose) Injection	CLINIMIX 8/14 sulfite‑free (8% Amino Acid in 14% Dextrose) Injection
	Dextrose Hydrous, USP (g/100 mL)	5	10	15	20	5	10	14
	Amino Acids (g/100 mL)	4.25	4.25	5	5	6	8	8
	Total Nitrogen (mg/100 mL)	702	702	826	826	990	1320	1320
Essential Amino Acids (mg/100 mL)	Leucine	311	311	365	365	438	584	584
	Isoleucine	255	255	300	300	360	480	480
	Valine	247	247	290	290	348	464	464
	Lysine (added as the hydrochloride salt)	247	247	290	290	348	464	464
	Phenylalanine	238	238	280	280	336	448	448
	Histidine	204	204	240	240	288	384	384
	Threonine	179	179	210	210	252	336	336
	Methionine	170	170	200	200	240	320	320
	Tryptophan	77	77	90	90	108	144	144
Nonessential Amino Acids (mg/100 mL)	Alanine	880	880	1035	1035	1242	1656	1656
	Arginine	489	489	575	575	690	920	920
	Glycine	438	438	515	515	618	824	824
	Proline	289	289	340	340	408	544	544
	Serine	213	213	250	250	300	400	400
	Tyrosine	17	17	20	20	24	32	32
Anion Profile (mEq/L)^*	Acetate^†	37	37	42	42	53	71	71
Anion Profile (mEq/L)^*	Chloride^‡	17	17	20	20	24	32	32
	pH^§(Range)	6.0 (4.5 to 7.0)	6.0 (4.5 to 7.0)	6.0 (4.5 to 7.0)	6.0 (4.5 to 7.0)	6.0 (4.5 to 7.0)	6.0 (4.5 to 7.0)	6.0 (4.5 to 7.0)
	Osmolarity (mOsmol/L) (calc)	675	930	1255	1505	850	1308	1520
Caloric Content (kcal/L)	From Dextrose	170	340	510	680	170	343	477
	From Amino Acids	170	170	200	200	240	320	320
	TOTAL (Dextrose and Amino Acids)	340	510	710	880	410	663	797

* Balanced by ions from amino acids.

† Derived from glacial acetic acid (for pH adjustment).

‡ Contributed by lysine hydrochloride and hydrochloric acid (for pH adjustment).

§ pH of sulfite-free amino acid injection in the outlet port chamber may be adjusted with glacial acetic acid and pH of dextrose injection port chamber may be adjusted with hydrochloric acid.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The use of CLINIMIX is contraindicated in:

Patients with known hypersensitivity to one or more amino acids or dextrose [see Warnings and Precautions (5.2)].
Patients with inborn errors of amino acid metabolism due to risk of severe metabolic and neurologic complications.
Patients with pulmonary edema or acidosis due to low cardiac output.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates

SPL UNCLASSIFIED SECTION

Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes due to pulmonary embolism have occurred. CLINIMIX contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)], the infusion set and catheter should also periodically be checked for precipitates.

5.2 Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Hypersensitivity/infusion reactions including anaphylaxis have been reported with CLINIMIX. Stop infusion immediately and treat patient accordingly if any signs or symptoms of a hypersensitivity reaction develop. Signs or symptoms may include: hypotension, hypertension, peripheral cyanosis, tachycardia, dyspnea, vomiting, nausea, urticaria, rash, pruritus, erythema, hyperhidrosis, pyrexia, and chills.

5.3 Risk of Infections

SPL UNCLASSIFIED SECTION

Patients who require parenteral nutrition are at high risk of infections because the nutritional components of these solutions can support microbial growth. Infection and sepsis may also occur as a result of the use of intravenous catheters to administer parenteral nutrition.

The risk of infection is increased in patients with malnutrition-associated immunosuppression, hyperglycemia exacerbated by dextrose infusion, long-term use and poor maintenance of intravenous catheters, or immunosuppressive effects of other concomitant conditions, drugs, or other components of the parenteral formulation (e.g., lipid emulsion).

To decrease the risk of infection, ensure aseptic technique in catheter placement and maintenance, as well as aseptic technique in the preparation and administration of the nutritional formula.

Monitor for signs and symptoms (including fever and chills) of early infections, including laboratory test results (including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device and insertion site for edema, redness and discharge.

5.4 Refeeding Syndrome

SPL UNCLASSIFIED SECTION

Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intakes.

5.5 Hyperglycemia or Hyperosmolar Hyperglycemic State

SPL UNCLASSIFIED SECTION

When using CLINIMIX in patients with diabetes mellitus, impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death. Patients with dehydration, resulting in a transient reduction in glomerular filtration rate and pre-renal azotemia, may be a greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels and treat hyperglycemia to maintain optimum levels while administering CLINIMIX. Insulin may be administered or adjusted to maintain optimal blood glucose levels during CLINIMIX administration.

5.6 Vein Damage and Thrombosis

SPL UNCLASSIFIED SECTION

Solutions with osmolarity of 900 mOsm/L or greater must be infused through a central catheter. CLINIMIX solutions containing more than 5% dextrose have an osmolarity greater than or equal to 900 mOsm/L. CLINIMIX 4.25/10, 5/15, 5/20, 8/10 and 8/14 are indicated for administration into a central vein only, such as the superior vena cava [see Dosage and Administration (2.2)]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis.

CLINIMIX 4.25/5 and 6/5 are indicated for peripheral administration, or may be infused into a central vein [see Dosage and Administration (2.2)]. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

5.7 Hepatobiliary Disorders

SPL UNCLASSIFIED SECTION

Hepatobiliary disorders are known to develop in some patients without preexisting liver disease who receive parenteral nutrition, including cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure. The etiology of these disorders is thought to be multifactorial and may differ between patients.

Increase in blood ammonia levels and hyperammonemia may occur in patients receiving amino acid solutions. In some patients this may indicate hepatic insufficiency or the presence of an inborn error of amino acid metabolism [see Contraindications (4) ].

Monitor liver function parameters and ammonia levels. Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

5.8 Aluminum Toxicity

SPL UNCLASSIFIED SECTION

CLINIMIX contains no more than 25 mcg/L of aluminum. The aluminum contained in CLINIMIX may reach toxic levels with prolonged administration in patients with impaired kidney function. Preterm infants are at a greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Patients with impaired kidney function, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

5.9 Risk of Parenteral Nutrition Associated Liver Disease

SPL UNCLASSIFIED SECTION

Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis. The exact etiology is unknown and is likely multifactorial. If CLINIMIX treated patients develop liver test abnormalities consider discontinuation or dosage reduction.

5.10 Electrolyte Imbalance and Fluid Overload

SPL UNCLASSIFIED SECTION

Patients with abnormal renal function due to pre-renal azotemia, renal obstruction, or intrinsic kidney disease may be at increased risk of electrolyte and fluid volume imbalance. Patients with cardiac insufficiency due to left ventricular systolic dysfunction are susceptible to excess fluid accumulation. Use CLINIMIX with caution in patients with cardiac insufficiency or kidney disease. CLINIMIX dosage may require adjustment with specific attention to fluid, protein, and electrolyte content in these patients.

Monitor renal function parameters. Patients developing signs of kidney disease should be assessed early by a clinician knowledgeable in kidney disease in order to determine the appropriate CLINIMIX dosage and other treatment options.

5.11 Monitoring/Laboratory Tests

SPL UNCLASSIFIED SECTION

Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment.

Patients receiving CLINIMIX should be monitored frequently and their electrolyte requirements individualized.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.1)]
Hypersensitivity reactions [see Warnings and Precautions (5.2)]
Risk of Infections [see Warnings and Precautions (5.3)]
Refeeding syndrome [see Warnings and Precautions (5.4)]
Hyperglycemia or hyperosmolar hyperglycemic state [see Warnings and Precautions (5.5)]
Vein damage and thrombosis [see Warnings and Precautions (5.6)]
Hepatobiliary disorders [see Warnings and Precautions (5.7)]
Parenteral Nutrition Associated Liver Disease [see Warnings and Precautions (5.9) ]
Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.10)]

The following adverse reactions from voluntary reports or clinical studies have been reported with CLINIMIX. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Diuresis
Extravasation
Glycosuria
Hyperglycemia
Hyperosmolar coma

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

There are no adequate or well-controlled studies in pregnant women with CLINIMIX. Additionally, animal reproduction studies have not been conducted with amino acids and electrolytes and dextrose. It is not known whether CLINIMIX can cause fetal harm when administered to a pregnant woman.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. However, the estimated background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.

Clinical Considerations

Disease-Associated Maternal and/or Embryo-Fetal Risk

Based on clinical practice guidelines, parenteral nutrition should be considered in cases of severe maternal malnutrition where nutritional requirements cannot be fulfilled by the enteral route because of the risks to the fetus associated with severe malnutrition, such as preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality.

8.2 Lactation

LACTATION SECTION

Risk Summary

It is not known whether CLINIMIX is present in human milk. There are no data on the effects of CLINIMIX on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CLINIMIX and any potential adverse effects on the breastfed child from CLINIMIX or from the underlying maternal condition.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of CLINIMIX in pediatric patients have not been established by adequate and well-controlled studies. Use of dextrose, amino acid infusions and electrolytes in pediatric patients is based on clinical practice [see Dosage and Administration (2.8)].

Newborns, especially those born premature and with low birth weight, are at increased risk of developing hypo – or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects. Hypoglycemia in the newborn can cause prolonged seizures, coma and brain damage. Hyperglycemia has been associated with intraventricular hemorrhage, late onset bacterial and fungal infection, retinopathy of prematurity, necrotizing enterocolitis, bronchopulmonary dysplasia, prolonged length of hospital stay, and death. Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes.

Because of immature renal function, preterm infants receiving prolonged treatment with CLINIMIX may be at risk of aluminum toxicity [see Warnings and Precautions (5.8)].

Patients, including pediatric patients, may be at risk for Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.9)].

Hyperammonemia is of special significance in infants (birth to two years). This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. It is essential that blood ammonia be measured frequently in infants [see Warnings and Precautions (5.7) ].

8.5 Geriatric Use

GERIATRIC USE SECTION

Clinical studies of CLINIMIX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from other younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

10 OVERDOSAGE

OVERDOSAGE SECTION

An increased infusion rate of CLINIMIX cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance [see Warnings and Precautions (5.5, 5.10)].

Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.

Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

11 DESCRIPTION

DESCRIPTION SECTION

CLINIMIX sulfite-free (amino acids in dextrose) injection for intravenous use consists of sterile, nonpyrogenic, hypertonic solutions in a dual chamber container.

The outlet port chamber contains essential and nonessential amino acids. The formulas for the individual amino acids found in CLINIMIX sulfite-free (amino acids in dextrose) injections are provided in Table 8.

Table 8: Formulas for Amino Acids
Essential Amino Acids
Leucine	(CH₃)₂ CHCH₂CH (NH₂) COOH
Isoleucine	CH₃CH₂CH (CH₃) CH (NH₂) COOH
Valine	(CH₃)₂ CHCH (NH₂) COOH
Lysine (added as the hydrochloride salt)	H₂N (CH₂)₄ CH (NH₂) COOH
Phenylalanine	(C₆H₅) CH₂ CH (NH₂) COOH
Histidine	(C₃H₃N₂) CH₂CH (NH₂) COOH
Threonine	CH₃CH (OH) CH (NH₂) COO
Methionine	CH₃S (CH₂)2 CH (NH₂) COOH
Tryptophan	(C₈H₆N) CH₂ CH (NH₂) COOH
Nonessential Amino Acids
Alanine	CH₃CH (NH₂) COOH
Arginine	H₂NC (NH) NH (CH₂)3 CH (NH₂) COOH
Glycine	H₂NCH₂COOH
Proline	[(CH₂)₃ NH CH] COOH
Serine	HOCH₂CH (NH₂) COOH
Tyrosine	[C₆H₄ (OH)] CH₂CH (NH₂) COOH

The injection port chamber contains dextrose. Dextrose, USP, is chemically designated D-glucose, monohydrate (C₆H₁₂O₆ • H₂O) and has the following structure:

Dextrose is derived from corn.

See Table 7 for composition, pH, osmolarity, ionic concentration and caloric content of the admixed product [see Dosage Forms and Strengths (3)].

The dual chamber container is a lipid-compatible plastic container (PL 2401 Plastic).

CLINIMIX contains no more than 25 mcg/L of aluminum.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

CLINIMIX is used as a supplement of nutrition in patients, providing macronutrients (amino acids and dextrose) parenterally.

The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.

The administered dextrose is oxidized to carbon dioxide and water, yielding energy.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The disposition of infused amino acids and dextrose, are essentially the same as those absorbed from ordinary food.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

CLINIMIX (amino acids in dextrose) injection (sulfite-free) is available in 1000 mL and 2000 mL volumes (See Table 9).

Table 9: CLINIMIX Formulations (per 07-19-00-3604 and BE-30-03-648)
After mixing, the product represents	1000 mL Code and NDC Number	2000 mL Code and NDC Number
CLINIMIX 4.25/5 sulfite‑free (4.25% Amino Acid in 5% Dextrose) Injection	Code 2B7726 NDC 0338‑1133‑03	Code 2B7704 NDC 0338‑1089‑04
CLINIMIX 4.25/10 sulfite‑free (4.25% Amino Acid in 10% Dextrose) Injection	Code 2B7727 NDC 0338‑1134‑03	Code 2B7705 NDC 0338‑1091‑04
CLINIMIX 5/15 sulfite‑free (5% Amino Acid in 15% Dextrose) Injection	Code 2B7730 NDC 0338‑1137‑03	Code 2B7709 NDC 0338‑1099‑04
CLINIMIX 5/20 sulfite‑free (5% Amino Acid in 20% Dextrose) Injection	Code 2B7731 NDC 0338‑1138‑03	Code 2B7710 NDC 0338‑1101‑04
CLINIMIX 6/5 sulfite‑free (6% Amino Acid in 5% Dextrose) Injection	Code EADB9913 NDC 0338‑0198-06	_____
CLINIMIX 8/10 sulfite‑free (8% Amino Acid in 10% Dextrose) Injection	Code EADB9933 NDC 0338‑0188-06	Code EADB9935 NDC 0338‑0194-04
CLINIMIX 8/14 sulfite‑free (8% Amino Acid in 14% Dextrose) Injection	Code EADB9953 NDC 0338‑0180-06	Code EADB9955 NDC 0338‑0184-04

Table 9: CLINIMIX Formulations (per BE-30-04-047)

After mixing, the product represents	1000 mL Code and NDC Number	2000 mL Code and NDC Number
CLINIMIX 4.25/5 sulfite‑free (4.25% Amino Acid in 5% Dextrose) Injection	Code 2B7726L NDC 0338‑7001-01	Code 2B7704L NDC 0338‑7003-01
CLINIMIX 4.25/10 sulfite‑free (4.25% Amino Acid in 10% Dextrose) Injection	Code 2B7727L NDC 0338‑7005-01	Code 2B7705L NDC 0338‑7007-01
CLINIMIX 5/15 sulfite‑free (5% Amino Acid in 15% Dextrose) Injection	Code 2B7730L NDC 0338‑7009-01	Code 2B7709L NDC 0338‑7011-01
CLINIMIX 5/20 sulfite‑free (5% Amino Acid in 20% Dextrose) Injection	Code 2B7731L NDC 0338‑7013-01	Code 2B7710L NDC 0338‑7015-01
CLINIMIX 6/5 sulfite‑free (6% Amino Acid in 5% Dextrose) Injection	Code EADB9913 NDC 0338‑0198-06	_____
CLINIMIX 8/10 sulfite‑free (8% Amino Acid in 10% Dextrose) Injection	Code EADB9933 NDC 0338‑0188-06	Code EADB9935 NDC 0338‑0194-04
CLINIMIX 8/14 sulfite‑free (8% Amino Acid in 14% Dextrose) Injection	Code EADB9953 NDC 0338‑0180-06	Code EADB9955 NDC 0338‑0184-04

Minimize exposure of CLINIMIX to heat and avoid excessive heat.

Protect from freezing.

Store CLINIMIX at room temperature (25°C/77°F) (may briefly store at up to 40°C/104°F).

Refrigerated storage is limited to 9 days once the protective overwrap has been opened.

Do not use if the protective overwrap has been previously opened or damaged.

For storage of admixed solutions see Dosage and Administration (2.3, 2.4).

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Inform patients, caregivers, or home healthcare providers of the following risks of CLINIMIX:

Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.1)]
Hypersensitivity reactions [see Warnings and Precautions (5.2)]
Risk of Infections [see Warnings and Precautions (5.3)]
Refeeding syndrome [see Warnings and Precautions (5.4)]
Hyperglycemia or hyperosmolar hyperglycemic state [see Warnings and Precautions (5.5)]
Vein damage and thrombosis [see Warnings and Precautions (5.6)]
Hepatobiliary disorders [see Warnings and Precautions (5.7)]
Aluminum toxicity [see Warnings and Precautions (5.8)]
Parenteral Nutrition Associated Liver Disease (PNALD) [see Warnings and Precautions (5.9)]
Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.10)]

SPL UNCLASSIFIED SECTION

Baxter Healthcare Corporation
Deerfield, IL 60015 USA
Baxter and Clinimix are registered trademarks of Baxter International Inc.
07-19-00-360 [Applies to Baxter Healthcare Corporation, Jayuya – Puerto Rico manufacturing plant]
BE-30-03-648 [Applies to Baxter SA, Lessines – Belgium manufacturing plant for Clinimix 6/5, Clinimix 8/10 and Clinimix 8/14]
BE-30-04-047 [Applies to Baxter SA, Lessines – Belgium manufacturing plant for the other Clinimix formulations]

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOT EXP
2B7727 NDC 0338-1134-03

CLINIMIX
4.25/10
SULFITE-FREE

(4.25% Amino Acids
in 10% Dextrose)
Injection

500 mL INJECTION PORT CHAMBER
20% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON
ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY
AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 10 g

ESSENTIAL AMINO ACIDS
LEUCINE 311 mg
ISOLEUCINE 255 mg
VALINE 247 mg
LYSINE (ADDED AS THE
HYDROCHLORIDE SALT) 247 mg
PHENYLALANINE 238 mg
HISTIDINE 204 mg
THREONINE 179 mg
METHIONINE 170 mg
TRYPTOPHAN 77 mg

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

LOT EXP

2B7726 NDC 0338-1133-03

CLINIMIX

4.25/5

SULFITE-FREE

(4.25% Amino Acids
in 5% Dextrose)
Injection

500 mL INJECTION PORT CHAMBER
10% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 5 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo

BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

LOT EXP

2B7704 NDC 0338-1089-04

CLINIMIX 4.25/5
SULFITE-FREE
(4.25% Amino Acid
in 5% Dextrose)
Injection

1000 mL INJECTION PORT CHAMBER
10% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTIONDEXTROSE HYDROUS USP 5 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
Representative Container Label 0338-1091-04

Container Label

LOT EXP

2B7705 NDC 0338-1091-04

CLINIMIX 4.25/10
SULFITE-FREE
(4.25% Amino Acid
in 10% Dextrose)
Injection

1000 mL INJECTION PORT CHAMBER
20% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION

DEXTROSE HYDROUS USP 10 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

LOT EXP

2B7730 NDC 0338-1137-03

CLINIMIX
5/15
SULFITE-FREE
(5% Amino Acid
in 15% Dextrose)
Injection

500 mL INJECTION PORT CHAMBER
30% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER
10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION

DEXTROSE HYDROUS USP 15 g

ESSENTIAL AMINO ACIDS
LEUCINE 365 mg
ISOLEUCINE 300 mg
VALINE 290 mg
LYSINE (ADDED AS THE
HYDROCHLORIDE SALT) 290 mg
PHENYLALANINE 280 mg
HISTIDINE 240 mg
THREONINE 210 mg
METHIONINE 200 mg
TRYPTOPHAN 90 mg

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

LOT EXP

2B7709 NDC 0338-1099-04

CLINIMIX
5/15
SULFITE-FREE
(5% Amino Acid
in 15% Dextrose)
Injection

1000 mL INJECTION PORT CHAMBER
30% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION

DEXTROSE HYDROUS USP 15 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

LOT EXP

2B7731 NDC 0338-1138-03

CLINIMIX
5/
SULFITE-FREE
(5% Amino Acid
in 20% Dextrose)
Injection

500 mL INJECTION PORT CHAMBER
40% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER
10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION

DEXTROSE HYDROUS USP 20 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

LOT EXP

2B7710 NDC 0338-1101-04

CLINIMIX
5/20
SULFITE-FREE
(5% Amino Acid
in 20% Dextrose)
Injection

1000 mL INJECTION PORT CHAMBER
40% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON

ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO 9 DAYS

A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY

AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION

DEXTROSE HYDROUS USP 20 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID

STERILE
SINGLE DOSE CONTAINER

ROOM TEMPERATURE (25°C/77°F)

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA

Container Label

EADB9913
NDC 0338-0198-01

1000 mL

CLINIMIX
6/5
SULFITE-FREE
(6% Amino Acid
in 5% Dextrose)
Injection

400 mL INJECTION PORT CHAMBER
12.5% Dextrose Injection USP
600 mL OUTLET PORT CHAMBER
10% Amino Acid Injection
Rx Only

ACTIVATE SEAL AND
MIX THOROUGHTLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS
ON ACTIVATION
AFTER MIXING THE PRODUCT REPRESENTS 1000 mL
REFRIGERATED STORAGE IS LIMITED TO 9 DAYS
ONCE OVERWRAP IS OPENED
A SLIGHT YELLOW COLOR DOES NOT ALTER THE
QUALITY AND EFFICACY OF THIS PRODUCT
ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 5 g

ESSENTIAL AMINO ACIDS
LEUCINE 438 mg
ISOLEUCINE 360 mg
VALINE 348 mg
LYSINE (ADDED AS THE
HYDROCHLORIDE SALT) 348 mg
PHENYLALANINE 336 mg
HISTIDINE 288 mg
THREONINE 252 mg
METHIONINE 240 mg
TRYPTOPHAN 108 mg

NONESSENTIAL AMINO ACIDS
ALANINE 1242 mg
ARGININE 690 mg
GLYCINE 618 mg
PROLINE 408 mg
SERINE 300 mg
TYROSINE 24 mg

mEq/L
ACETATE 53
CHLORIDE 24

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE

SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25ºC/77ºF)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

EXP LOT

BE-35-04-040

Container Label

EADP9933
NDC 0338-0188-01

1000 mL

CLINIMIX
8/10
SULFITE-FREE
(8% Amino Acid
in 10% Dextrose)
Injection

360 mL INJECTION PORT CHAMBER
28% Dextrose Injection USP
640 mL OUTLET PORT CHAMBER
12.5% Amino Acid Injection
Rx Only

ACTIVATE SEAL AND
MIX THOROUGHTLY BEFORE USE

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 10 g

ESSENTIAL AMINO ACIDS
LEUCINE 584 mg
ISOLEUCINE 480 mg
VALINE 464 mg
LYSINE (ADDED AS THE
HYDROCHLORIDE SALT) 464 mg
PHENYLALANINE 448 mg
HISTIDINE 384 mg
THREONINE 336 mg
METHIONINE 320 mg
TRYPTOPHAN 144 mg

NONESSENTIAL AMINO ACIDS
ALANINE 1656 mg
ARGININE 920 mg
GLYCINE 824 mg
PROLINE 544 mg
SERINE 400 mg
TYROSINE 32 mg

mEq/L
ACETATE 71
CHLORIDE 32

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE

SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25ºC/77ºF)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

EXP LOT

BE-35-04-041

Container Label

EADB9935
NDC 0338-0194-01

2000 mL

CLINIMIX
8/10
SULFITE-FREE
(8% Amino Acid
in 10% Dextrose)
Injection

720 mL INJECTION PORT CHAMBER
28% Dextrose Injection USP
1280 mL OUTLET PORT CHAMBER
12.5% Amino Acid Injection
Rx Only

ACTIVATE SEAL AND
MIX THOROUGHTLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON ACTIVATION
AFTER MIXING THE PRODUCT REPRESENTS 2000 mL
REFRIGERATED STORAGE IS LIMITED TO 9 DAYS
ONCE OVERWRAP IS OPENED
A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY AND
EFFICACY OF THIS PRODUCT
ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION
DEXTROSE HYDROUS USP 10 g

NONESSENTIAL AMINO ACIDS
ALANINE 1656 mg
ARGININE 920 mg
GLYCINE 824 mg
PROLINE 544 mg
SERINE 400 mg
TYROSINE 32 mg

mEq/L
ACETATE 71
CHLORIDE 32

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25ºC/77ºF)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

Exp Lot

BE-35-04-045

Container Label

EADB9953
NDC 0338-0180-01

1000 mL

CLINIMIX
8/14
SULFITE-FREE
(8% Amino Acid
in 14% Dextrose)
Injection

360 mL INJECTION PORT CHAMBER
39% Dextrose Injection USP
640 mL OUTLET PORT CHAMBER
12.5% Amino Acid Injection
Rx Only

ACTIVATE SEAL AND
MIX THOROUGHTLY BEFORE USE

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 14 g

NONESSENTIAL AMINO ACIDS
ALANINE 1656 mg
ARGININE 920 mg
GLYCINE 824 mg
PROLINE 544 mg
SERINE 400 mg
TYROSINE 32 mg

mEq/L
ACETATE 71
CHLORIDE 32

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25ºC/77ºF)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

EXP LOT

BE-35-04-043

Container Label

EADB9955
NDC 0338-0184-01

2000 mL

CLINIMIX
8/14
SULFITE-FREE
(8% Amino Acid
in 14% Dextrose)
Injection

720 mL INJECTION PORT CHAMBER
39% Dextrose Injection USP
1280 mL OUTLET PORT CHAMBER
12.5% Amino Acid Injection
Rx Only

ACTIVATE SEAL AND
MIX THOROUGHTLY BEFORE USE

CONTENTS OF EACH 100 mL OF THE
ADMIXED INJECTION
DEXTROSE HYDROUS USP 14 g

NONESSENTIAL AMINO ACIDS
ALANINE 1656 mg
ARGININE 920 mg
GLYCINE 824 mg
PROLINE 544 mg
SERINE 400 mg
TYROSINE 32 mg

mEq/L
ACETATE 71
CHLORIDE 32

BALANCED BY IONS FROM AMINO ACIDS

pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25ºC/77ºF)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

Exp Lot

BE-35-04-047

Container Label

2B7726L
NDC0338-7001-01

1000 mL

Barcode
(01) 00303387001012

CLINIMIX
4.25/10
SULFITE-FREE
(4.25% Amino Acids in 5% Dextrose)
Injection

500 mL INJECTION PORT CHAMBER
10% Dextrose Injection USP

500 mL OUTLET PORT CHAMBER

8.5% Amino Acid Injection
Rx Only

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR
INSTRUCTIONS ON ACTIVATION

AFTER MIXING THE PRODUCT
REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT
ALTER THE QUALITY AND EFFICACY OF
THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE
COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION
DEXTROSE HYDROUS USP 5 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

1600

1000

800

600

400

200

BE-35-05-077

EXP LOT

Container Label

2B7704L
NDC0338-7003-01

2000mL

Barcode
(01) 00303387003016

CLINIMIX
4.25/5

SULFITE-FREE

(4.25% Amino Acids
in 5% Dextrose)
Injection

1000 mL INJECTION PORT CHAMBER
10% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS
ON ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT ALTER THE
QUALITY AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 5 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

2000

1600

1000

800

600

400

200

BE-35-05-073

EXP LOT

Container Label

2B7727L
NDC0338-7005-01

1000mL

Barcode
(01) 00303387005010

CLINIMIX
4.25/10
SULFITE-FREE
(4.25% Amino Acids in 10% Dextrose)
Injection

CENTRAL LINE INFUSION ONLY

500 mL INJECTION PORT CHAMBER
20% Dextrose Injection USP
500 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection
Rx Only

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR
INSTRUCTIONS ON ACTIVATION

AFTER MIXING THE PRODUCT
REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT
ALTER THE QUALITY AND EFFICACY OF
THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE
COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION
DEXTROSE HYDROUS USP 10 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

1600

1000

800

600

400

200

BE-35-05-078

EXP LOT

Container Label

2B7705L
NDC0338-7007-01

2000mL

Barcode
(01) 00303387007014

CLINIMIX
4.25/10

SULFITE-FREE

(4.25% Amino Acids
in 10% Dextrose)
Injection

CENTRAL LINE INFUSION ONLY

1000 mL INJECTION PORT CHAMBER
20% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
8.5% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS
ON ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT ALTER THE
QUALITY AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 10 g

NONESSENTIAL AMINO ACIDS
ALANINE 880 mg
ARGININE 489 mg
GLYCINE 438 mg
PROLINE 289 mg
SERINE 213 mg
TYROSINE 17 mg

mEq/L
ACETATE 37
CHLORIDE 17

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

2000

1600

1000

800

600

400

200

BE-35-05-074

EXP LOT

Container Label

2B7730L
NDC0338-7009-01

1000mL

Barcode
(01) 00303387009018

CLINIMIX
5/15
SULFITE-FREE
(5% Amino Acids
in 15% Dextrose)
Injection

CENTRAL LINE INFUSION ONLY

500 mL INJECTION PORT CHAMBER
30% Dextrose Injection USP
500 mL OUTLET PORT CHAMBER
10% Amino Acid Injection
Rx Only

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR
INSTRUCTIONS ON ACTIVATION

AFTER MIXING THE PRODUCT
REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT
ALTER THE QUALITY AND EFFICACY OF
THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE
COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION
DEXTROSE HYDROUS USP 15 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

1600

1000

800

600

400

200

BE-35-05-079

EXP LOT

Container Label

2B7709L
NDC0338-7011-01

2000mL

Barcode
(01) 00303387011011

CLINIMIX
5/15

SULFITE-FREE

(5% Amino Acids
in 15% Dextrose)
Injection

CENTRAL LINE INFUSION ONLY

1000 mL INJECTION PORT CHAMBER
30% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS
ON ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT ALTER THE
QUALITY AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 15 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

2000

1600

1000

800

600

400

200

BE-35-05-075

EXP LOT

Container Label

2B7731L
NDC0338-7013-01

1000mL

Barcode
(01) 00303387013015

CLINIMIX
5/20
SULFITE-FREE
(5% Amino Acids
in 20% Dextrose)
Injection

CENTRAL LINE INFUSION ONLY

500 mL INJECTION PORT CHAMBER
40% Dextrose Injection USP
500 mL OUTLET PORT CHAMBER
10% Amino Acid Injection
Rx Only

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR
INSTRUCTIONS ON ACTIVATION

AFTER MIXING THE PRODUCT
REPRESENTS 1000 mL

REFRIGERATED STORAGE IS LIMITED TO
9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT
ALTER THE QUALITY AND EFFICACY OF
THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE
COMPATIBILITY

CONTENTS OF EACH 100 mL OF THE ADMIXED INJECTION
DEXTROSE HYDROUS USP 20 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

1600

1000

800

600

400

200

BE-35-04-996

EXP LOT

Container Label

2B7710L
NDC0338-7015-01

2000mL

Barcode
(01) 00303387015019

CLINIMIX
5/20

SULFITE-FREE

(5% Amino Acids
in 20% Dextrose)
Injection

CENTRAL LINE INFUSION ONLY

1000 mL INJECTION PORT CHAMBER
40% Dextrose Injection USP

1000 mL OUTLET PORT CHAMBER
10% Amino Acid Injection

Rx Only

ACTIVATE SEAL AND
MIX THOROUGHLY BEFORE USE

SEE PRESCRIBING INFORMATION FOR INSTRUCTIONS ON
ACTIVATION

AFTER MIXING THE PRODUCT REPRESENTS 2000 mL

REFRIGERATED STORAGE IS LIMITED
TO 9 DAYS ONCE OVERWRAP IS OPENED

A SLIGHT YELLOW COLOR DOES NOT ALTER THE
QUALITY AND EFFICACY OF THIS PRODUCT

ASK PHARMACIST ABOUT ADDITIVE COMPATIBILITY

2D Datamatrix (GS1):
NDC, LOT, EXP

2D Datamatrix
Barcode

CONTENTS OF EACH 100 mL OF THE ADMIXED
INJECTION
DEXTROSE HYDROUS USP 20 g

NONESSENTIAL AMINO ACIDS
ALANINE 1035 mg
ARGININE 575 mg
GLYCINE 515 mg
PROLINE 340 mg
SERINE 250 mg
TYROSINE 20 mg

mEq/L
ACETATE 42
CHLORIDE 20

BALANCED BY IONS FROM AMINO ACIDS
pH ADJUSTED WITH GLACIAL ACETIC ACID
AND HYDROCHLORIC ACID

STERILE
SINGLE DOSE CONTAINER

STORE AT ROOM TEMPERATURE (25°C/77°F)
IN UNOPENED OVERWRAP

AVOID EXCESSIVE HEAT

PROTECT FROM FREEZING

SEE PRESCRIBING INFORMATION

Baxter Logo
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN BELGIUM

2000

1600

1000

800

600

400

200

BE-35-04-988

EXP LOT

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
cb89b86a-369e-4204-8910-ae797c503af3	Product name	1	20230706
d4880ace-a516-8c47-8dfd-73a4ba5887d7	Product name	2	20180830
7cda52fc-125f-421c-8fea-bc1974370c49	Product name	2	20180703
48747306-602a-42cc-957b-5b0c69158eee	Product name	1	20180604
0ca1d589-929b-4b33-bc5b-1d84abdafa6a	Product name	1	20150324
fc363c46-397b-4476-ac0f-70e43e8e4592	Product name	1	20150324
1681bc73-b05f-12c3-1075-382ae39f449c	Product name	1	20140508
db5ebcdb-b6ae-21cd-4dc5-76cd84b5578b	Product name	1	20140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3	Product name	1	20140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0338-1133-03	ML - Milliliter	0338-1133	fbb20887-1360-4149-beeb-62f196f3baa2	1	2012-07-24
0338-1089-04	ML - Milliliter	0338-1089	1b1bd8a0-6dbb-443a-a593-77e48e326250	1	2012-07-24
0338-1134-03	ML - Milliliter	0338-1134	c8a3d332-379f-41a3-b16f-e0e11b7444a7	1	2012-07-24
0338-1091-04	ML - Milliliter	0338-1091	4bc1c3bf-9716-464e-8c61-fcdcdefe772e	1	2012-07-24
0338-1137-03	ML - Milliliter	0338-1137	ecaadfa2-2564-472a-9399-5c0569594ccb	1	2012-07-24
0338-1099-04	ML - Milliliter	0338-1099	ff1b8680-84e6-4c59-a9dd-fcc2e95b7e4d	1	2012-07-24
0338-1138-03	ML - Milliliter	0338-1138	49379db0-f57f-4242-bad8-ae8ffac74e7c	1	2012-07-24
0338-1101-04	ML - Milliliter	0338-1101	d6b08181-c18e-4e98-9cc4-e664e212b16a	1	2012-07-24
0338-7001-01	ML - Milliliter	0338-7001	3f18feb1-6acb-45df-b1d9-513caff8094e	1	2025-11-13
0338-7001-06	ML - Milliliter	0338-7001	505ae18a-59d7-44f3-a589-7d2bf7169e68	1	2025-11-13
0338-7003-01	ML - Milliliter	0338-7003	b746eacf-8093-4340-956a-cfb8956945e9	1	2025-11-13
0338-7003-04	ML - Milliliter	0338-7003	38ab92e0-f9bf-42c5-8fd1-ecaa843d8107	1	2025-11-13
0338-7011-01	ML - Milliliter	0338-7011	06446ff9-0184-457d-a049-6548dad2e197	1	2024-10-04
0338-7011-04	ML - Milliliter	0338-7011	1b19a544-86e1-437c-a7a7-5bdbc864be43	1	2024-10-04
0338-7015-01	ML - Milliliter	0338-7015	93566c21-9d77-4d08-ad50-540ae5a84907	1	2025-11-13
0338-7015-04	ML - Milliliter	0338-7015	117ff48e-bf95-4db5-bb71-e00c44cdc254	1	2025-11-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
ALANINE	ACTIVE INGREDIENT	OF5P57N2ZX	2
ARGININE	ACTIVE INGREDIENT	94ZLA3W45F	2
DEXTROSE	ACTIVE INGREDIENT	IY9XDZ35W2	2
GLYCINE	ACTIVE INGREDIENT	TE7660XO1C	2
HISTIDINE	ACTIVE INGREDIENT	4QD397987E	2
ISOLEUCINE	ACTIVE INGREDIENT	04Y7590D77	2
LEUCINE	ACTIVE INGREDIENT	GMW67QNF9C	2
LYSINE	ACTIVE INGREDIENT	K3Z4F929H6	2
METHIONINE	ACTIVE INGREDIENT	AE28F7PNPL	2
PHENYLALANINE	ACTIVE INGREDIENT	47E5O17Y3R	2
PROLINE	ACTIVE INGREDIENT	9DLQ4CIU6V	2
SERINE	ACTIVE INGREDIENT	452VLY9402	2
THREONINE	ACTIVE INGREDIENT	2ZD004190S	2
TRYPTOPHAN	ACTIVE INGREDIENT	8DUH1N11BX	2
TYROSINE	ACTIVE INGREDIENT	42HK56048U	2
VALINE	ACTIVE INGREDIENT	HG18B9YRS7	2
ALANINE	ACTIVE MOIETY	OF5P57N2ZX	2
ARGININE	ACTIVE MOIETY	94ZLA3W45F	2
DEXTROSE	ACTIVE MOIETY	IY9XDZ35W2	2
GLYCINE	ACTIVE MOIETY	TE7660XO1C	2
HISTIDINE	ACTIVE MOIETY	4QD397987E	2
ISOLEUCINE	ACTIVE MOIETY	04Y7590D77	2
LEUCINE	ACTIVE MOIETY	GMW67QNF9C	2
LYSINE	ACTIVE MOIETY	K3Z4F929H6	2
METHIONINE	ACTIVE MOIETY	AE28F7PNPL	2
PHENYLALANINE	ACTIVE MOIETY	47E5O17Y3R	2
PROLINE	ACTIVE MOIETY	9DLQ4CIU6V	2
SERINE	ACTIVE MOIETY	452VLY9402	2
THREONINE	ACTIVE MOIETY	2ZD004190S	2
TRYPTOPHAN	ACTIVE MOIETY	8DUH1N11BX	2
TYROSINE	ACTIVE MOIETY	42HK56048U	2
VALINE	ACTIVE MOIETY	HG18B9YRS7	2
ACETIC ACID	INACTIVE INGREDIENT	Q40Q9N063P	2
NITROGEN	INACTIVE INGREDIENT	N762921K75	2
WATER	INACTIVE INGREDIENT	059QF0KO0R	2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 23 matching rows.

CLINIMIX
Leucine, Phenylalanine, Lysine, Methionine, Isoleucine, Valine, Histidine, Threonine, Tryptophan, Alanine, Glycine, Arginine, Proline, Serine, Tyrosine, Dextrose
LEUCINE
PHENYLALANINE
LYSINE
METHIONINE
ISOLEUCINE
VALINE
HISTIDINE
THREONINE
TRYPTOPHAN
ALANINE
GLYCINE
ARGININE
PROLINE
SERINE
TYROSINE
DEXTROSE
ANHYDROUS DEXTROSE
ACETIC ACID
WATER
NITROGEN
HYDROCHLORIC ACID

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
0338-1133	0338-1133-03
0338-1089	0338-1089-04
0338-1134	0338-1134-03
0338-1091	0338-1091-04
0338-1137	0338-1137-03
0338-1099	0338-1099-04
0338-1138	0338-1138-03
0338-1101	0338-1101-04
0338-0198	0338-0198-01, 0338-0198-06
0338-0188	0338-0188-01, 0338-0188-06
0338-0194	0338-0194-01, 0338-0194-04
0338-0180	0338-0180-01, 0338-0180-06
0338-0184	0338-0184-01, 0338-0184-04
0338-7001	0338-7001-01, 0338-7001-06
0338-7003	0338-7003-01, 0338-7003-04
0338-7005	0338-7005-01, 0338-7005-06
0338-7007	0338-7007-01, 0338-7007-04
0338-7009	0338-7009-01, 0338-7009-06
0338-7011	0338-7011-01, 0338-7011-04
0338-7013	0338-7013-01, 0338-7013-06
0338-7015	0338-7015-01, 0338-7015-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 11 · 412 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
LEUCINE	GMW67QNF9C	ACTIB
PHENYLALANINE	47E5O17Y3R	ACTIB
LYSINE	K3Z4F929H6	ACTIB
METHIONINE	AE28F7PNPL	ACTIB
ISOLEUCINE	04Y7590D77	ACTIB
VALINE	HG18B9YRS7	ACTIB
HISTIDINE	4QD397987E	ACTIB
THREONINE	2ZD004190S	ACTIB
TRYPTOPHAN	8DUH1N11BX	ACTIB
ALANINE	OF5P57N2ZX	ACTIB
GLYCINE	TE7660XO1C	ACTIB
ARGININE	94ZLA3W45F	ACTIB
PROLINE	9DLQ4CIU6V	ACTIB
SERINE	452VLY9402	ACTIB
TYROSINE	42HK56048U	ACTIB
DEXTROSE	IY9XDZ35W2	ACTIB
ACETIC ACID	Q40Q9N063P	IACT
WATER	059QF0KO0R	IACT
NITROGEN	N762921K75	IACT
LEUCINE	GMW67QNF9C	ACTIB
PHENYLALANINE	47E5O17Y3R	ACTIB
LYSINE	K3Z4F929H6	ACTIB
METHIONINE	AE28F7PNPL	ACTIB
ISOLEUCINE	04Y7590D77	ACTIB
VALINE	HG18B9YRS7	ACTIB
HISTIDINE	4QD397987E	ACTIB
THREONINE	2ZD004190S	ACTIB
TRYPTOPHAN	8DUH1N11BX	ACTIB
ALANINE	OF5P57N2ZX	ACTIB
GLYCINE	TE7660XO1C	ACTIB
ARGININE	94ZLA3W45F	ACTIB
PROLINE	9DLQ4CIU6V	ACTIB
SERINE	452VLY9402	ACTIB
TYROSINE	42HK56048U	ACTIB
DEXTROSE	IY9XDZ35W2	ACTIB
ACETIC ACID	Q40Q9N063P	IACT
WATER	059QF0KO0R	IACT
NITROGEN	N762921K75	IACT
LEUCINE	GMW67QNF9C	ACTIB
PHENYLALANINE	47E5O17Y3R	ACTIB

Source Document#

Source XML · Source PDF

Older Hydrated Versions#

Version, Effective date, Source table
Version	Effective date	Source	Hydrated
13	2021-04-13	full-release	2026-05-31 21:33:58

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 55 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Maximum daily exposure	Match
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates
ACETIC ACID	ACETIC ACID	Q40Q9N063P	INJECTION / INTRAVENOUS	827 mg	Exact identifier — unii+route+dosage form 55 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 13 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	Approval date
N020734-001	CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	2.75%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-002	CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	2.75%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-005	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	2.75%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-007	CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	4.25%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-008	CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	4.25%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-010	CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	4.25%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-011	CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	4.25%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-014	CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	5%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-015	CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	5%;15GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-016	CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	5%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-017	CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	5%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-018	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	5%;35GM/100ML	INJECTABLE / INJECTION	1997-09-29
N020734-019	CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER	AMINO ACIDS; DEXTROSE	8%;14GM/100ML	INJECTABLE / INJECTION	2021-04-13

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 14 · 533 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N020734-001	CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	2.75%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-002	CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	2.75%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-005	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	2.75%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-007	CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	4.25%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-008	CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-010	CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	4.25%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-011	CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-014	CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	5%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-015	CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER	5%;15GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-016	CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	5%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-017	CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-018	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER	5%;35GM/100ML	INJECTABLE / INJECTION	1997-09-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N020734-019	CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER	8%;14GM/100ML	INJECTABLE / INJECTION	2021-04-13	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N020734-001	CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	2.75%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-002	CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	2.75%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-005	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	2.75%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-007	CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	4.25%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-008	CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-010	CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	4.25%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-011	CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-014	CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	5%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-015	CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER	5%;15GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-016	CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	5%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-017	CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-018	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER	5%;35GM/100ML	INJECTABLE / INJECTION	1997-09-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N020734-019	CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER	8%;14GM/100ML	INJECTABLE / INJECTION	2021-04-13	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N020734-001	CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	2.75%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-002	CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	2.75%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-005	CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	2.75%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-007	CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	4.25%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-008	CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-010	CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	4.25%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-011	CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-014	CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER	5%;10GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-015	CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER	5%;15GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-016	CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER	5%;20GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-017	CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-018	CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER	5%;35GM/100ML	INJECTABLE / INJECTION	1997-09-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N020734-019	CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER	8%;14GM/100ML	INJECTABLE / INJECTION	2021-04-13	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N020734-001	CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER	2.75%;5GM/100ML	INJECTABLE / INJECTION	1997-09-29	`31067a03dcf5…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
CLINIMIX	LEUCINE, PHENYLALANINE, LYSINE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, SERINE, TYROSINE, DEXTROSE	Baxter Healthcare Corporation	dccff103-8695-400c-a15d-cc2fd078760a	2021-04-13	Warnings, Adverse reactions	Exact identifier ndc (package): 0338-0194-04 ndc (package): 0338-1089-04 ndc (package): 0338-7005-06 ndc (package): 0338-7001-01 ndc (package): 0338-7007-04 ndc (package): 0338-0184-01 ndc (package): 0338-1137-03 ndc (package): 0338-1099-04 ndc (package): 0338-1138-03 ndc (package): 0338-7001-06 ndc (package): 0338-7009-06 ndc (package): 0338-7009-01 ndc (package): 0338-7015-01 ndc (package): 0338-0194-01 ndc (package): 0338-7015-04 ndc (package): 0338-0188-06 ndc (package): 0338-7011-04 ndc (package): 0338-7005-01 ndc (package): 0338-1133-03 ndc (package): 0338-1091-04 ndc (package): 0338-0198-01 ndc (package): 0338-7007-01 ndc (package): 0338-0198-06 ndc (package): 0338-7013-01 ndc (package): 0338-7003-04 ndc (package): 0338-7003-01 ndc (package): 0338-1134-03 ndc (package): 0338-7011-01 ndc (package): 0338-0180-01 ndc (package): 0338-7013-06 ndc (package): 0338-0188-01 ndc (package): 0338-0180-06 ndc (package): 0338-1101-04 ndc (package): 0338-0184-04 ndc (product): 0338-7011 ndc (product): 0338-1089 ndc (product): 0338-0180 ndc (product): 0338-1137 ndc (product): 0338-0194 ndc (product): 0338-7015 ndc (product): 0338-1134 ndc (product): 0338-0198 ndc (product): 0338-1101 ndc (product): 0338-1091 ndc (product): 0338-7009 ndc (product): 0338-1138 ndc (product): 0338-1133 ndc (product): 0338-1099 ndc (product): 0338-7003 ndc (product): 0338-0184 ndc (product): 0338-7007 ndc (product): 0338-7001 ndc (product): 0338-0188 ndc (product): 0338-7005 ndc (product): 0338-7013 ndc11 (package): 00338700101 ndc11 (package): 00338700106 ndc11 (package): 00338700901 ndc11 (package): 00338109904 ndc11 (package): 00338109104 ndc11 (package): 00338701104 ndc11 (package): 00338019401 ndc11 (package): 00338701301 ndc11 (package): 00338108904 ndc11 (package): 00338700301 ndc11 (package): 00338700304 ndc11 (package): 00338700906 ndc11 (package): 00338700704 ndc11 (package): 00338018806 ndc11 (package): 00338701504 ndc11 (package): 00338700506 ndc11 (package): 00338700501 ndc11 (package): 00338019404 ndc11 (package): 00338113403 ndc11 (package): 00338018006 ndc11 (package): 00338018001 ndc11 (package): 00338701101 ndc11 (package): 00338700701 ndc11 (package): 00338113303 ndc11 (package): 00338113703 ndc11 (package): 00338701501 ndc11 (package): 00338113803 ndc11 (package): 00338019801 ndc11 (package): 00338019806 ndc11 (package): 00338018404 ndc11 (package): 00338110104 ndc11 (package): 00338701306 ndc11 (package): 00338018801 ndc11 (package): 00338018401 spl id: ff41ef10-43c8-4813-9b53-f7f2b9dbb468 spl set id: dccff103-8695-400c-a15d-cc2fd078760a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.